Xilio Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | — | Purchase | 25,000 | $0.69 | $17,250 | 70,000 | Jun 16, 2025 |
| Russo Rene | PRESIDENT AND CEO | Purchase | 36,289 | $0.68 | $24,677 | 281,172 | Jun 16, 2025 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Option Exercise | 5,000 | — | — | 5,000 | Jan 2, 2025 |
| Frankenfield Christopher James | Chief Financial Officer | Sale | 6,954 | $0.98 | $6,815 | 12,421 | Jan 1, 2025 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Option Exercise | 16,625 | — | — | 16,625 | Jan 1, 2025 |
| Russo Rene | PRESIDENT AND CEO | Option Exercise | 44,250 | — | — | 244,883 | Jan 1, 2025 |
| GILEAD SCIENCES, INC. | — | Purchase | 1,759,978 | $1.04 | $1,830,377 | 9,105,451 | Dec 18, 2024 |
| GILEAD SCIENCES, INC. | — | Purchase | 485,250 | $0.76 | $368,790 | 7,345,473 | Apr 2, 2024 |
| Atlas Venture Fund XI, L.P. | — | Sale | 733 | $0.64 | $469 | 2,019,563 | Feb 8, 2024 |
| Atlas Venture Associates Opportunity I, L.P. | — | Sale | 1,540 | $0.83 | $1,278 | 2,020,296 | Jan 11, 2024 |
| BCIP Life Sciences Associates, LP | — | Purchase | 4,011 | $9.84 | $39,468 | 2,780,413 | Dec 8, 2021 |
| SV7 Impact Medicine Fund LP | — | Purchase | 312,500 | $16.00 | $5,000,000 | 1,613,632 | Oct 26, 2021 |
| Deerfield Mgmt L.P. | — | C | 756,472 | — | — | 756,472 | Oct 26, 2021 |
| FIL Ltd | — | C | 218,705 | — | — | 218,705 | Oct 26, 2021 |
| FMR LLC | — | C | 789,473 | — | — | 815,788 | Oct 26, 2021 |
| SV7 (IMF) GP LLP | — | C | 302,588 | — | — | 1,301,132 | Oct 26, 2021 |
| Takeda Ventures, Inc. | — | C | 1,475,121 | — | — | 1,475,121 | Oct 26, 2021 |
| RiverVest Venture Fund IV, L.P. | — | Purchase | 250,000 | $16.00 | $4,000,000 | 1,441,444 | Oct 26, 2021 |
| Rock Springs Capital Master Fund LP | — | C | 756,472 | — | — | 756,472 | Oct 26, 2021 |
| Merck KGaA | — | C | 416,060 | — | — | 416,060 | Oct 26, 2021 |
| BAY CITY CAPITAL LLC | — | Purchase | 312,500 | $16.00 | $5,000,000 | 1,129,490 | Oct 26, 2021 |
| Atlas Venture Opportunity Fund I, L.P. | — | Purchase | 187,500 | $16.00 | $3,000,000 | 735,942 | Oct 26, 2021 |
| Alexandria Venture Investments, LLC | — | C | 166,423 | — | — | 166,423 | Oct 26, 2021 |